About: 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $12.93 (+8.11%)
FDMT NASDAQ 4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc share price
Atividade de preço de FDMT
Último preço
$ 12,780
Variação (24h)
-0,15 USD (1,16%)
Volume
847.86K
Volume (média 4 sem.)
-
Abertura
$ 13,00
Variação do dia
$ 12,57 - $ 13,46
Fechamento anterior
$ 12,93
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
FDMT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals